Amplifica Reveals Results from Its First-in-Human Trial For Androgenic Alopecia

Amplifica, a clinical-stage biopharmaceutical company based in San Diego, has announced the results from its first-in-human trial of AMP-303, an intradermal injection treatment for androgenic alopecia (AGA). Amplifica has several AGA treatments in the pipeline, including AMP-203 (osteopontin) and AMP-601 (SCUBE3).

What is AMP-303?

We spoke about AMP-303 last year when they announced the initiation of its trial. While we don’t have the full details about the product, we know that it is a proprietary formulation developed for intradermal injection into the scalp to treat AGA. 

Trial Results

According to the press release, male participants aged 18-45 with AGA were included in the study. These participants were split based on the duration of hair loss: recent onset – 3 to 5 years and long-standing hair loss – over 10 years. The participants received intradermal injections of AMP-303 on one side of the scalp and a placebo on the other. 

  • A statistically significant number of participants showed a greater than 15% increase in non-vellus hair count from baseline compared to a placebo at 60 days post-treatment.
  • A statistically significant number of participants showed a greater than 10% increase compared to placebo at 150 days post-treatment.
  • Adverse events were mild in severity, with no severe adverse events reported.

Amplifica says: “The success of the AMP-303 study not only validates our approach but also sets the foundation for advancing additional programs in Amplifica’s pipeline”.

Reflections

While the results might be positive, it is difficult to determine the clinical relevance without images or raw data. Hopefully, Amplifica can provide these in the future.

Let us know what you think about the results in the comments below.

Posted in

21 Comments

  1. Oguz on September 30, 2024 at 11:00 am

    Did they start a clinicla trial and was it the phase 1? Will the phase 2 now start?

  2. Keith on September 30, 2024 at 11:20 am

    Does it need FDA clearance?

  3. LJ on September 30, 2024 at 12:46 pm

    Since there is efficacy studied here, does that mean it’s not Ph1?

    • looking on October 2, 2024 at 10:16 am

      lj, i’m not sure but the way Ive been following I think this was some sort of hybrid phase1/2 and that the type of substance they r using can make it thru trials faster than a typical drug. its like an injection like a botox

  4. YoYo on September 30, 2024 at 2:26 pm

    I mean this is definitely encouraging alongside Pelage’s results too. I feel Amplifica and Pelage are the beacon of hopes for hair loss sufferers until a more permanent solution such as Stemson or Fukuda will come out

    • Anna on October 1, 2024 at 5:02 am

      Hi Yoyo, I see you are a very active member of the forum and often provide useful insights. What’s your person view on when hair cloning will be commercial available? Like how many years from now? Thank you.

      • YoYo on October 8, 2024 at 11:51 pm

        Hi Anna, thanks for the kind words. I don’t want to say a year and damper your expectations, however I will say this. Science and technology is better than ever before and for the first time there has been a clear effort in the field of hair loss. Amplifica, Pelage, Eirion etc. When it comes to hair cloning there are two companies I’m interested in, Stemson and Fukuda, (not a fan of Tsuji). Stemson have confirmed their clinical trials for 2026, and Fukuda have confirmed clinical trials in the next 5 years (this was last year). I can see it coming to fruition POSSIBLY in 2029/2030 depending on factors such as, where they do the trials (such as Japan or South K.) how the results look like etc. But Stemson is the real deal and they seem genuinely interested in making hair loss a thing of the past. It’s a long process but I think we’ll be fine, as long as Amplifica or Pelage can pull through (I’m leaning more so on Pelage) we can have a safer and more effective treatment until hair cloning can be a reality.

        • Keith on October 9, 2024 at 9:52 am

          Pelage seems legit, look at their team. PhDs and MDs from Harvard. We are closer, 5 more years, lol but technology is more powerful than ever and making headway!

        • Viktoriya on October 9, 2024 at 5:18 pm

          Yoyo, thank you so much 🙂 Let’s pray that our hair cloning will cure us by 2030.

        • Hope on October 10, 2024 at 2:27 pm

          Hello Yoyo. I recently went to a dermatologist who is involved in research studies, conferences, and quite up to date. He has a YouTube channel in Spanish and although I had already heard it in his videos, he repeated it to me again. “Until 10 years from now there will be nothing that can be of similar effectiveness to anti-androgens in pills or Minoxidil and they will be of the cell regeneration type but not more powerful than these.” I would like to know why you are so optimistic. It is difficult for me to be one since 17 years ago my baldness had already been cured with cloning.

        • Jens on October 10, 2024 at 3:27 pm

          Whats your opinion about FOL005 or Follicopeptide? Coegin is planning for launch already next year.

    • LJ on October 1, 2024 at 12:26 pm

      Agreed

  5. dwain phillis on October 1, 2024 at 4:03 am

    still no cure but have a con covid cure in minutes kittke odd ha should make you think

  6. Baldman, helper of the bald on October 1, 2024 at 5:12 am

    This is very unhealthy, do not spend your life following every little baldness “cure”, it is not an affliction but the mental processes endured doing this definitely is one.

    This way madness lies.

  7. zero hope on October 3, 2024 at 10:21 pm

    Maybe they will have better luck with AMP-601 (SCUBE3).
    Or not,who knows.

  8. Ted on October 3, 2024 at 11:01 pm

    no pictures?
    if I had a product that was effective at growing hair, you better believe that I would be publishing dozens of pictures everywhere.

  9. Steven Schmidt on October 6, 2024 at 12:27 am

    I sure wish Amplifica would stop putting their time, effort and money in what I consider possible “secondary treatments” and get to the real ‘meat’ of things! Yes, I’m talking about “SCUBE3” also known as AMP-60. This was the big item of hair loss news in 2022! I was really disappointed when I found out that Amplifica was not using a SCUBE3 based treatment for their first human trails! Perhaps I missed something regarding these other items, but with all SCUBE3’s media coverage and excitement came out in 2022, it looked to me like the most promising potential treatment we’ve had in a long, long while. I just can’t get too excited about any new treatment that may offer a possible 10-15% increase in non-vellus hair counts. Heck, we have treatments now that can do that or better!

  10. Tony on October 6, 2024 at 3:58 am

    So what IS AMP-303? It’s not SCUBE3 or Osteopontin, but a 15% increase in hair count it promising, was this applied to bare scalp? or to areas that still had some hairs?

  11. Michael on October 14, 2024 at 6:44 am

    I agree with Ted – Pictures of scalps showing more hair on one side, but…………

    • Juvir on October 27, 2024 at 9:08 am

      This Solution is associated with cancer. So, it doesn’t matter if it can make grow a full head of hair; because it is involved in cancer it won’t see the market.

  12. Keith on October 28, 2024 at 11:02 am

    When do we think please or amplifica will be available?

Leave a Comment





Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.